Development of a certified reference material for anti-β2-glycoprotein I IgG - commutability studies

被引:9
|
作者
Monogioudi, Evanthia [1 ]
Martos, Gustavo [1 ,2 ]
Sheldon, Joanna [3 ]
Meroni, Pier Luigi [4 ]
Trapmann, Stefanie [1 ]
Zegers, Ingrid [1 ]
机构
[1] European Commiss, Joint Res Ctr JRC, Geel, Belgium
[2] Int Bur Weights & Measures, Sevres, France
[3] St George Hosp, Prot Reference Unit, London, England
[4] Univ Milan, IRCCS Inst Auxol Italiano, Milan, Italy
关键词
autoimmune testing; certified reference materials; harmonization; proteinase; 3; standardization; STANDARDIZATION;
D O I
10.1515/cclm-2020-0995
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: In this paper, we describe the steps followed for the development of a certified reference material for immunoglobulin G antibodies against beta 2-glycoprotein I (also known as apolipoprotein H). These steps include processing of the material, commutability, the impact of dilution, the appropriate reconstitution conditions, homogeneity and stability during transport and storage. Methods: We analysed 69 clinical samples from patients suffering from antiphospholipid syndrome with several commercial enzyme-linked immunosorbent assays (ELISA) purchased from in vitro diagnostic manufacturers. Results: Analysis of the results indicated that the candidate reference material can be safely freeze-dried, and that the user should carefully follow the reconstitution instructions as small changes in e.g. temperature may have unwanted effects. The statistical analysis of the commutability studies indicated that the analytical response of the reference material upon dilution is similar to that of clinical samples, and that correlation between results may differ from assay to assay. Finally yet importantly, the presented and developed candidate reference material is commutable for most assays tested, homogeneous and stable. Conclusions: Immunoglobulin G antibodies against beta 2-glycoprotein I are associated with a higher risk of thrombosis and pregnancy complications. Their measurement is essential for the diagnosis and monitoring of antiphospholipid syndrome. These antibodies are detected by specific immunoassays, routinely used in clinical diagnostics, but various of these methods show enormous variability, in part due to the lack of a reference material.
引用
收藏
页码:325 / 332
页数:8
相关论文
共 50 条
  • [1] [IgG anti-β2-glycoprotein I β2-glycoprotein I] immune complexes in patients with antiphospholipid (aPL) syndrome
    Biasiolo, A
    Rampazzo, P
    Brocco, P
    Rosato, A
    Barbero, F
    Pengo, V
    THROMBOSIS RESEARCH, 1998, 91 (03) : S124 - S124
  • [2] β2-glycoprotein I, anti-β2-glycoprotein 1, and fibrinolysis
    Yasuda, S
    Atsumi, T
    Ieko, M
    Koike, T
    THROMBOSIS RESEARCH, 2004, 114 (5-6) : 461 - 465
  • [3] Anti-β2-glycoprotein I antibodies
    Willis, Rohan
    Pierangeli, Silvia S.
    YEAR IN IMMUNOLOGY, 2013, 1285 : 44 - 58
  • [4] Anti-β2-glycoprotein I antibodies
    Tsutsumi, A
    Ichikawa, K
    Matsuura, E
    Koike, T
    LUPUS, 1998, 7 : S98 - S102
  • [5] β2-glycoprotein I and anti-β2-glycoprotein I antibodies:: Where are we now?
    Inanç, M
    Radway-Bright, EL
    Isenberg, DA
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (12): : 1247 - 1257
  • [6] IgA anti-?2-glycoprotein I antibodies
    Carrock Sewell
    Arthritis Research & Therapy, 3 (1)
  • [7] Anti-β2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to β2-glycoprotein I with low affinity:: Dimerization of β2-glycoprotein I induces a significant increase in anti-β2-glycoprotein I antibody affinity
    Sheng, YH
    Kandiah, DA
    Krilis, SA
    JOURNAL OF IMMUNOLOGY, 1998, 161 (04): : 2038 - 2043
  • [8] IgG anti-β2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus
    Rothschild, BM
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (02) : 455 - 455
  • [9] Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I
    A. Artenjak
    I. Locatelli
    H. Brelih
    D. M. Simonič
    Z. Ulcova-Gallova
    J. Swadzba
    J. Musial
    T. Iwaniec
    L. Stojanovich
    F. Conti
    G. Valesini
    T. Avčin
    J. W. Cohen Tervaert
    Y. Shoenfeld
    M. Blank
    A. Ambrožič
    S. Sodin-Semrl
    B. Božič
    S. Čučnik
    Immunologic Research, 2015, 61 : 35 - 44
  • [10] Anti-β2-glycoprotein I antibodies:: clinical significance
    Tincani, A
    Spatola, L
    Cinquini, M
    Cattaneo, R
    Meroni, P
    Balestrieri, G
    LUPUS, 1998, 7 : S107 - S109